Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
BACCI trial (atezolizumab): what clinicians have said so far
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
- NCT02873195 ↗
- Completed
- Academic and Community Cancer Research United
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on BACCI (atezolizumab in refractory metastatic colorectal cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BACCI so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 7 posts on X |
The trial
ClinicalTrials.gov- Official title
- BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Colorectal Carcinoma; Recurrent Colorectal Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Atezolizumab; Bevacizumab; Capecitabine; Laboratory Biomarker Analysis; Placebo
- Arms
- Arm I (atezolizumab, bevacizumab, capecitabine) · Experimental
- Arm II (placebo, bevacizumab, capecitabine) · Active comparator
- Enrollment
- 133
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- Academic and Community Cancer Research United with National Cancer Institute (NCI)
- Start
- Jul 7, 2017
- Primary completion
- Mar 6, 2023
- Results posted
- Yes
- Registry record
- NCT02873195 · updated Aug 23, 2024
Publications
linked from the registry- Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, Bekaii-Saab T. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1;5(2):e2149040. doi: 10.1001/jamanetworkopen.2021.49040. PubMed 35179586